Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRX

Rang in aandelen #4177
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aandeelprijs
$31.49
Laatst gesynchroniseerd: 2026-07-21
Marktkapitalisatie
$3.85B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
49.88%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)

Categorie

Healthcare
Aandelsplitsingen voor Catalyst Pharmaceuticals, Inc. (CPRX)
Het aandeel Catalyst Pharmaceuticals, Inc. (symbool: CPRX) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel CPRX dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen CPRX.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL